TIM-3 expression has been recently associated with poor prognosis in a number of cancer types, including UC [119,120,121]; because of the implication of TIM-3 overexpression in T-cell dysfunction and exhaustion, several TIM-3 inhibitors are currently being studied in advanced cancer. Here, HAVCR2 is linked to cancer.